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RESUM
Els esteroides sintetitzats en el sistema nerviós s’han anomenat neuroesteroides perquè es creu
que estan dirigits a actuar exclusivament en les cèll. ules del cervell. Utilitzant com a model
les vies esteroidogèniques definides en els teixits endocrins perifèrics, s’ha demostrat que les
cèll. ules glials del cervell poden convertir el colesterol en pregnenolona, que és el precursor d’u-
na sèrie d’esteroides moduladors de les funcions neuronals, com és la dihidroepiandrosterona
(DHEA), un dels esteroides neuroactius principals sintetitzats en el cervell. Nogensmenys, les
dades obtingudes fins avui no aporten elements clau de l’existència d’aquesta via en el cervell,
tals com l’activitat 17α-hidroxilasa/17-20-liasa citocrom P450 (CYP17) responsable de la forma-
ció de DHEA en els teixits perifèrics. Això suggereix l’existència d’una via diferent, específica
de cèll. ula cerebral, per a la síntesi de DHEA. El present manuscrit vol revisar els esforços per
explorar i caracteritzar el mecanisme de síntesi i regulació del neuroesteroide DHEA. El nostre
objectiu a llarg termini és comprendre les bases neuroquímiques de la biosíntesi esferoidal en
el cervell. Durant els darrers anys, hem aportat evidència de l’existència d’una via alternativa
de la biosíntesi de DHEA nova, específica de cervell i independent de CYP17. Tanmateix, hem
demostrat que la formació de la DHEA en el cervell està regulada per l’estrès oxidatiu, i desen-
cadenada pel ferro i el pèptid β-amiloide tant in vitro com in vivo. En conclusió, aquestes dades
suggereixen l’existència d’una via específica cerebral per a la biosíntesi de DHEA.Paraules clau: neuroesteroides, colesterol, andrògens, CYP17, neuropatologia.
SUMMARY
Steroids synthesized in the nervous system were termed neurosteroids because they are be-
lieved to be targeted exclusively to brain cells. Using as a model the steroidogenic pathway
defined in peripheral endocrine tissues, it has been shown that brain glial cells can convert
cholesterol to pregnenolone, precursor of a number of steroid modulators of neuronal func-
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tions including dehydroepiandrosterone (DHEA), one of the main neuroactive steroids syn-
thesized in brain. However, the data presented up to date did not find key elements of this
pathway in brain, such as the 17α-hydroxylase/17,20-lyase cytochrome P450 (CYP17) activity
responsible forDHEA formation in peripheral tissues, suggesting the presence of distinct, brain
(cell)-specific, pathway for DHEA biosynthesis. The present manuscript reviews our efforts to
explore and characterize the mechanism of synthesis and regulation of the neurosteroidDHEA.
Our long-term goal is to understand the neurochemical basis of steroid biosynthesis in brain.
During the past years we provided evidence for a novel, brain cell-specific CYP17-independent
alternative pathway forDHEA biosynthesis. Moreover, we demonstrated that brainDHEA for-
mation is regulated by oxidative stress, and triggered by iron and β-amyloid peptide both in
vitro andin vivo. In conclusion, these data suggest that there is a brain-specific DHEA biosyn-
thetic pathway.Keywords: neurosteroids, cholesterol, androgens, CYP17, neuropathology.
It is now well established that steroid hor-
mones act by regulating gene expression,
inducing cellular processes such as growth
and differentiation in steroid-sensitive tissues.
The genomic effects of steroids are medi-
ated through proteins members of the su-
perfamily of steroid hormone receptors, a
group of intracellular transcription factors
(Beato, 1989). Steroids also have rapid, non-
genomic effects, particularly in the brain,
that were first observed in the 1940s (Se-
lye, 1941; Selye, 1942). These actions initially
involved anesthetic metabolites of proges-
terone, but have since been expanded to in-
clude a large number of steroid compounds.
These non-genomic activities are character-
ized by extremely rapid effects, lasting from
milliseconds to minutes, and do not require
interaction with steroid hormone receptors
(Orchinik et al., 1993). In the CNS, these ef-
fects are thought to involve steroid modu-
lation of membrane-bound neurotransmitter
receptors (Majewska, 1987; Lambert et al.,
1995), including the GABAA receptor com-
plex and the NMDA class of glutamate re-
ceptors (Mellon, 1994). Neuroactive steroids
have been intensively studied in recent years,
due to their great appeal as potential drugs
for treatment of a number of neuropatholog-
ical and clinical conditions. Because of their
lipophilic structure, steroids can easily diffuse
across the blood-brain barrier if given periph-
erally, thereby bypassing the issues of drug
delivery from the circulation across the blood-
brain barrier and into the brain. Further-
more, the amounts of steroid needed to induce
changes in neural activity are extremely low,
typically in the nanomolar range. The term
neurosteroids was initially used by Baulieu
and coworkers (Baulieu et al., 1990) to desig-
nate the steroid hormone, DHEA and preg-
nenolone and their sulfated forms, which
could be measured in the brain at concentra-
tions independent of the known peripheral
sources, such as the adrenal glands or the go-
nads (Corpechot et al., 1981; Corpechot et al.,
1983).
DHEA is a naturally occurring steroid pro-
duced by the adrenal cortex in humans and
is the most abundant steroid in the blood un-
der normal conditions (Kroboth et al., 1999).
In adult humans, most DHEA secreted by the
adrenal glands is released as the sulfated form
(DHEA-S). Together,DHEA andDHEA-S are
the precursors for ~50% of androgens pro-
duced in adult men, ~75% of estrogen in pre-
menopausal women, and 100% of estrogen
produced in postmenopausal women. Under
normal conditions, DHEA is secreted with
cortisol in response to ACTH stimulation of
the adrenal cortex. There is some debate as
to whether the function of DHEA is solely as
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a precursor for androgen biosynthesis or if it
has some biological activity of its own. Be-
cause there is no known intracellular steroid
receptor for DHEA it seems likely that the
majority of its actions are due to its conver-
sion to estrogen and testosterone in target tis-
sues. Importantly, DHEA production is age-
dependent, with adrenal production peaking
at about age 25 and declining to 15-20% of
peak levels by age 80 (Baulieu et al., 1998).
DHEA was first isolated in the brain in
1981 (Corpechot et al., 1981), and shown
to be present in the brain at higher lev-
els than in the periphery (Corpechot et al.,
1981; Kroboth et al., 1999). Furthermore, brain
DHEA levels seem to be independent of pe-
ripheral steroid producing tissues (Corpechot
et al., 1981, 1993; Baulieu et al., 1998), and
will persist for up to two weeks following
the removal of the adrenal glands and go-
nads in rats. This suggests either a sequestra-
tion of DHEA in the brain, or de novo syn-
thesis of DHEA within the brain itself. In
recent years, much interest has been directed
towards DHEA in the brain and the role of
DHEA in aging (Baulieu, 1996). DHEA is
considered to be a neuroactive steroid, and
as such, can modulate neuronal excitability
through a number of different mechanisms
(Baulieu et al., 1998). DHEA has been shown
to enhance memory in male mice (Roberts
et al., 1987; Flood et al., 1992) and long-term
potentiation in the hippocampus (Yoo et al.,
1996).DHEA can potentiate neuronalNMDA
responses via sigma receptors (Bergeron et
al., 1996), which may account for some of its
memory-enhancing effects. There is also some
evidence that DHEA may be important in
differentiation of glia and neurons during de-
velopment (Roberts et al., 1987) and in cortical
organization (Compagnone et al., 1998). There
has also been a great deal of research trying to
linkDHEAwith cognitive function associated
with various pathologies, for a number of rea-
sons. Age-related decrease in DHEA is one of
the most striking changes in endocrine func-
tion over one’s lifetime (Parker, 1999). DHEA,
as well as other neurosteroids, may be in-
volved in modulating learning and memory
(Roberts et al., 1987; Flood et al., 1992; Yoo et al.,
1996) although there is not yet convincing ev-
idence that DHEA is involved in human age-
related cognitive decline or dementia (Guazzo
et al., 1996; Berr et al., 1996; Wolf et al., 1997a,
1997b). Ultimately, despite the huge public in-
terest and use, the role of DHEA in the brain
is, at this time, still unknown.
BIOSYNTHESIS OF DHEA
IN THE PERIPHERY
All steroid hormones are derived from cho-
lesterol. The initial step in steroid biosynthe-
sis is the metabolism of cholesterol to preg-
nenolone, a process that occurs on the inner
mitochondrial membrane, and is catalyzed
by the cytochrome P450 side chain cleav-
age enzyme (CYP11A1). The rate-limiting
step in steroid biosynthesis is the transport
of cholesterol from the cytosol to the inner
mitochondrial membrane, a process that is
mediated by a complex of proteins on the
cytoplasmic side of the outer mitochondrial
membrane (Papadopoulos, 1993; Hall, 1994).
DHEA is synthesized in the microsomal com-
partment of cells of adrenal cortex (as well
as other steroidogenic cell types) by the me-
tabolism of pregnenolone via the cytochrome
P450 17α-hydroxylase/17,20-lyase (CYP17).
The expression of the CYP17 enzyme mRNA
is regulated by ACTH and LH and their
second messenger cAMP (Whitlock, 1986).
Further PCR analysis has demonstrated two
products amplified from rat adrenal glands
and brain, but only one product in testis
(Sanne et al., 1995), suggesting that alter-
native, tissue-specific, splice variants of the
CYP17 enzyme exist. The enzyme activity can
be also induced by pituitary hormones and
cAMP (Whitlock, 1986) and although the en-
zyme is active on its own, high levels of
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17,20-lyase activity require the presence of cy-
tochrome P450 oxidoreductase as an electron
donor (Sanne et al., 1995). In the non-human
primate adrenal gland, CYP17 is expressed in
the zona fasciculata, where it is involved in the
production of glucocorticoids, and in the zona
reticularis, where it mediates androgen pro-
duction (Mesiano et al., 1993). In the human
adrenal, DHEA is present in the zona fasci-
culate/reticularis (Miller et al., 1997; Parker,
1999). The development of compounds affect-
ing CYP17 activity allowed to better examine
the role of the enzyme in in vitro and in vivo
settings. CYP17 activity can be inhibited by
SU 10603, a pyridine derivative (LaCagnin et
al., 1989) or the imidazole fungicide ketocona-
zole (Albertson et al., 1988).
In the rat, where the majority of studies on
DHEA synthesis and its neuroactive effects
have been done, CYP17 activity and protein
expression are limited to the theca cells of the
ovary and the Leydig cells of the testis, both
primary sources of estrogen and testosterone
respectively (Berr et al., 1996; LeGoascogne et
al., 1991). Although CYP17 mRNA is present
in the rat adrenal (Stromstedt et al., 1995) and
embryonic rat central nervous system (Com-
pagnone et al., 1995) no CYP17 immunoreac-
tivity and bioactivity were detected in either
the adrenal cortex (Berr et al., 1996) or the
neonatal and adult rat brain (LeGoascogne
et al., 1987; Baulieu et al., 1998; Cascio et al.,
2001). These data indicate that the presence
of an mRNA transcript does not necessarily
reflect the expression of a biologically active
protein. This may explain many studies show-
ing that rats do not make high levels of pe-
ripheral DHEA (Hall, 1985), and is intriguing
in light of the high levels of DHEA present in
brain (Baulieu et al., 1998).
BIOSYNTHESIS OF DHEA
IN THE CENTRAL NERVOUS SYSTEM
An issue in characterizing the physiologi-
cal role of neurosteroids has been determin-
ing their source. Two possibilities have been
considered: diffusion of steroids made in pe-
ripheral steroidogenic tissues, such as the go-
nads and adrenals, across the blood-brain bar-
rier, or de novo steroid biosynthesis within the
brain itself. Baulieu and colleagues demon-
strated that the levels of neurosteroids in the
rat brain are very high, and persist for up
to two weeks after the removal of peripheral
steroidogenic organs (Corpechot et al., 1981;
Corpechot et al., 1983; Akwa et al., 1991; Cor-
pechot et al., 1993; Baulieu et al., 1998). In
search of de novo synthesis of steroids in brain,
the assumption was then made that steroido-
genesis in brain will be the same as that de-
scribed in classical peripheral steroidogenic
tissues, such as adrenal and gonads.
In peripheral steroid biosynthesis, steroido-
genesis begins with the transport of the pre-
cursor cholesterol from intracellular stores
across the outer mitochondrial membrane to
the inner mitochondrial membrane, where
CYP11A1 is located (Hall, 1994; Jefcoate,
2002). This process is facilitated by two pro-
teins, the peripheral-type benzodiazepine re-
ceptor (PBR; Papadopoulos, 1993; Papado-
poulos et al., 1997) and the steroidogenic acute
regulatory protein (StAR; Stocco et al., 1996).
PBR was found to be abundant in the glial cell
of theCNS (Papadopoulos, 1993; Papadopou-
los et al., 2005) and PBR drug ligands were
shown to stimulate pregnenolone formation
in vitro and in vivo (Papadopoulos et al., 1992;
Costa et al., 1994; Papadopoulos et al., 2005).
StAR was also found to be present in the
CNS, although in limited amounts (King et al.,
2002); its function in neurosteroidogenesis is
under investigation.
As noted above, cholesterol in mitochon-
dria is metabolized to pregnenolone by
CYP11A1. The localization of CYP11A1 to the
white matter of the rat brain was established
by immunocytochemistry (LeGoascogne et al.,
1987), suggesting that oligodendrocytes are a
source of neurosteroids in the brain (LeGoas-
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cogne et al., 1987; Robel et al., 1995). Pri-
mary cultures of mixed glia (Hu et al., 1987,
1989; Jung-Testas et al., 1989; Robel et al.,
1995) and gliomas (Guarneri et al., 1992; Pa-
padopoulos et al., 1992) were then shown to
metabolize cholesterol to pregnenolone and
progesterone. Furthermore, mRNA and pro-
tein for the CYP11A1 and other steroid me-
tabolizing enzymes have been found in spe-
cific brain areas and cell types (Jung-Testas
et al., 1989; Mellon et al., 1992; Stromstedt et
al., 1995; Kohchi et al., 1998). In peripheral
tissues, pregnenolone is subsequently metab-
olized to various steroid products. Indeed, the
conversion of pregnenolone to progesterone
in rat glial cultures (Hu et al., 1987; Hu et
al., 1989; Jung-Testas et al., 1989; Robel et al.,
1995) and the production of progesterone and
5α-reduced metabolites of progesterone by rat
brain (Jung-Testas et al., 1989; Melcangi et al.,
1994) have been demonstrated. Interestingly,
these metabolites were shown to be positive
allosteric modulators of the GABAA recep-
tor complex (Majewska, 1987; Lambert et al.,
1995).
Despite these observations indicating that
steroids in brain may indeed be formed via the
same enzymatic pathways as those described
in adrenals and gonads, there is controversy
about the mechanism of DHEA synthesis.
DHEA, the first neurosteroid described is a
major neuroactive steroid, and constitutes a
main portion of the neurosteroids found in
the rat brain (Corpechot et al., 1981; Baulieu et
al., 1998). However, convincing evidence for
CYP17 expression and activity in the brain
has been more difficult to find. First, conflict-
ing reports exist on the presence of CYP17
mRNA transcripts in the CNS. Although
CYP17 mRNA has been found by in situ hy-
bridization to be present during rat embryonic
development (Compagnone et al., 1995), there
is no solid evidence for CYP17 mRNA in the
adult (Mellon et al., 1993; Stromstedt et al.,
1995; Kohchi et al., 1998). A similar contradic-
tion has been shown in the rat adrenal, a tissue
devoid of CYP17 activity (Hall, 1994) where
the CYP17 mRNA is present (Stromstedt et al.,
1995). Moreover, there has been no demon-
stration on the presence of either CYP17 pro-
tein expression (LeGoascogne et al., 1991; Cas-
cio et al., 1999, 2001) or enzyme activity (Akwa
et al., 1991; Baulieu et al., 1998; Cascio et al.,
1999, 2001) in adult rat brain. Detailed stud-
ies using incubations of the precursor preg-
nenolone with brain slices, homogenates, and
microsomes, with primary cultures of mixed
glia cells, or with astrocytes and neurons of
rat and mouse embryos failed to demonstrate
any CYP17 activity (Baulieu et al., 1998; Cas-
cio et al., 2001). Interestingly, in other species
such as in the songbird zebra finch, CYP17 ac-
tivity is also absent from brain (Schlinger et al.,
1999).
In contrast to these findings, Hojo (Hojo
et al., 2004) recently reported that the adult
male rat hippocampus synthesizes estradiol
from pregnenolone by CYP17 and cytochrome
P450 aromatase localized in neurons. CYP17
immunoreactivity was found in pyramidal
neurons of CA1-CA3 regions of hippocampus
and in the granule cells in the dentate gyrus.
CYP17 expression was confirmed by west-
ern blot and RT-PCR. Moreover, the authors
reported that hippocampal cubic slices con-
verted radiolabeled pregnenolone to estradiol
through DHEA and testosterone (Hojo et al.,
2004). It is evident that such findings stirred
an enormous interest since other laboratories
have been unable to demonstrate such data in
adult brain slices, cells or microsomes (Com-
pagnone et al., 1995; Baulieu et al., 1998; Cascio
et al., 1999, 2001). The most critical finding was
the demonstration for the first time of CYP17
activity. However, a closer analysis of the data
presented demonstrated that considering the
expression level of CYP17 in hippocampus,
which is at least 50-100-fold less than in testis,
and the 1 to 10,000 transformation rate of radi-
olabeled pregnenolone achieved in the exper-
iments presented by the authors, the reported
activity could not account for the formation of
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0.42 ng DHEA per gram brain tissue (Corpe-
chot et al., 1981).
Taken together these findings suggest that
DHEA is formed in brain via a CYP17-
independent pathway. This possibility is also
supported by clinical findings from patients
with CYP17 defects (Yanase, 1995; Zachmann,
1995). Deficiency in CYP17 in humans is not
lethal (Yanase, 1995; Zachmann, 1995). Be-
cause of the importance of CYP17 in testos-
terone and estrogen formation (Corpechot et
al., 1993), male pseudohermaphroditism or
absence of pubertal development has been
described for the CYP17-deficient humans
(Yanase, 1995; Zachmann, 1995). However,
no patient has shown neurological or mental
problems. Considering thatDHEA can modu-
late neuronal excitability (Baulieu et al., 1998),
enhance memory in male mice (Roberts et al.,
1987; Flood et al., 1992), enhance long-term
potentiation in the hippocampus (Yoo et al.,
1996), potentiate neuronal NMDA responses
(Bergeron et al., 1996) and foremost being im-
portant in differentiation of glia and neurons
during development (Roberts et al., 1987) and
in cortical organization (Compagnone et al.,
1998) one wonders how the brain could func-
tion without DHEA. The only logical expla-
nation would be that in humans deficient in
CYP17 brain DHEA is formed via a CYP17-
independent mechanism.
These data leave us with a crucial question:
how the brain is able to synthesize high lev-
els of DHEA if the CYP17 enzyme is absent,
present are extremely low levels or inactive?
Many concepts in science are based on dog-
mas, such as that of CYP17 being indispens-
able for DHEA synthesis. Thus, to answer the
question one has to go against that dogma.
This dogma is based exclusively on in vitro
data, because there is not any in vivo data
available since there are no specific/exclusive
inhibitors for CYP17 that do not inhibit other
cytochrome P450s and CYP17 knock-out ani-
mal models. This dogma was first challenged
openly by Dr. S. Lieberman in a review
(Lieberman et al., 2001), where he even ques-
tioned the role of CYP17 in the biosynthesis
of gonadal steroids. In 1994, Prasad et al. re-
ported the formation of DHEA in organic
extracts of rat brain treated with different ox-
idizing and reducing agents (Prasad et al.,
1994). This paper proposed the existence of al-
ternative precursors for neurosteroids in the
brain that could be metabolized under appro-
priate oxidative conditions. This was the first
indication that there could be a novel CYP17-
independent mechanism for steroid biosyn-
thesis in the brain. Since the Prasad et al. study
examined this alternative pathway in an arti-
ficial and non-physiological system, we have
looked for it in living cells. Studies in our labo-
ratory using Fe++ ions as a redox tool demon-
strated the presence of an alternative pathway
for DHEA synthesis in rat C6-2B glioma cells,
which lack both the CYP17 mRNA and pro-
tein (Cascio et al., 1998, 1999).
Adding FeSO4 to C6 cells increased the
synthesis of both pregnenolone and DHEA.
Even in the presence of aminoglutethimide,
an inhibitor of CYP11A1, FeSO4 increased
the synthesis of both steroids, indicating that
the Fe2+-sensitive process does not involve
CYP11A1. Likewise the FeSO4-induced for-
mation of DHEA was not blocked by the
CYP17 inhibitor, SU-10603. These results sug-
gest that the FeSO4-induced synthesis of
DHEA as well as of pregnenolone in C6 cells
may be due to the fragmentation of in situ-
formed tertiary hydroperoxides. It is likely,
however, that the effect of the Fe2+ is not lim-
ited to this reaction. When exogenous preg-
nenolone was added to C6 microsomes, along
with FeSO4, the amount of DHEA formed
was greater than control values, indicating
that Fe2+ facilitated the conversion of preg-
nenolone to DHEA. Unlike the constituents
that are converted by Fe2+ to pregnenolone,
the precursor of DHEA in C6 cells is not sol-
uble in a 1:1 mixture of ether and ethylac-
etate. In search of the mechanism of DHEA
formation, we examined the nature of its pu-
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tative precursor using successive treatments
with reducing and oxidizing agents. C6 cells
were treated with KI (to reduce peroxy com-
pounds to their corresponding alcohols), then
with NaBH4 (to reduce ketones, including
preexisting DHEA, to alcohols) and finally
with NaIO4 (to oxidize glycols to carbonyl
products). Treatment of C6 cells with KI,
NaBH4 or HIO4 resulted in an increase in
DHEA synthesis in comparison to that of un-
treated cells, suggesting that a C17,C20-glycol
was the proximal precursor of DHEA. The
most obvious steroid glycol is pregn-5-ene-
3β,17,20-triol, in which case the initial per-
oxy precursor is 17-hydroperoxide of preg-
nenolone, which can be converted to DHEA
through a process of ketone formation by β-
fragmentation (Cascio et al., 1998). However,
the evidence presented does not exclude other
peroxy precursors, particularly one derived
from a sterol, like cholesterol, such as the
17,20-dihydroxycholesterol. In control dishes
DHEA was reduced to the diol by NaBH4.
From this it seems clear that a precursor of the
DHEA produced in C6 cells is a steroid where
both C-17 and C-20 are oxygenated (Cascio et
al., 1998).
This alternative pathway was subsequently
found in microsomes isolated from neona-
tal rat brain cortex and primary cultures of
rat glial cells (Cascio et al., 2001), but not
in other tissues examined. In contrast to the
C6-2B glioma cells, CYP17 mRNA and pro-
tein were found in immature rat oligodendro-
cyte precursors and mature oligodendrocytes.
In the presence of substrate (pregnenolone),
these cells made DHEA. However, addition
of Fe++ increased DHEA formation in these
cells. DHEA formation in the presence of
pregnenolone and Fe++ was not inhibited by
the CYP17 inhibitors SU-10603 and ketocona-
zole, indicating that the formation of DHEA
in oligodendrocytes occurs independently of
the CYP17 protein present in the cells (Cas-
cio et al., 1999; Cascio et al., 2001). These
data could also explain the data reported
by Hojo et al., (2004) because it shows that
pregnenolone can be metabolized to DHEA,
in a CYP17-independent manner, but in the
presence of prooxidants. It is likely that dur-
ing incubation of brain slices and cells such
conditions might occur if oxygen levels are
not carefully controlled. Isolated type I as-
trocytes do not express CYP17 mRNA or
protein, but will respond to Fe++ by pro-
ducing DHEA. Thus, DHEA production in
both types of cells occurred independently
of active CYP17. Furthermore, these results
suggest that in differentiating oligodendro-
cytes and astrocytes, DHEA is formed via an
oxidative stress-dependent alternative path-
way (Cascio et al., 1999). Another study also
demonstrated DHEA production when cul-
tures of isolated rat glial cells, but not brain
tissue, are incubated with pregnenolone as
a precursor (Zwain et al., 1999). However,
whether this reaction was mediated by CYP17
and the identity of the steroids formed remain
to be established.
We subsequently investigated the presence
of the alternative pathway in human glial cells
by treating them with FeSO4 and looking at
DHEA production. We found that both hu-
man oligodendrocytes and astrocytes produce
DHEA in response to FeSO4, but not human
neurons (Brown et al., 2000). This pathway
does not appear to be an artifact of cell culture,
because treating homogenates of human brain
with FeSO4 also resulted in DHEA produc-
tion (Brown et al., 2003). Moreover, we demon-
strated that DHEA formation by human cells
is regulated by the levels of intracellular free
radicals and can be blocked by antioxidants
such as Vitamin E (Brown et al., 2000). The
mechanism by which we detect the alternative
pathway activity, treatment with FeSO4, is a
harsh and non-physiologic environment, with
high levels of oxidative stress. This brought
up the question of whether or not this path-
way is relevant in vivo. We addressed this
question, in the case of Alzheimer’s disease
(AD), by treating cells in culture with β-
142 Y. LIU AND V. PAPADOPOULOS
amyloid (Aβ) and examining samples of hu-
man AD brain for evidence of the alternative
pathway. Recent data suggest that increased
oxidative stress and inflammation may play a
large role in the pathogenesis of AD (Markes-
bery, 1997). Aβ, a peptide important in the
pathogenesis of AD, has been shown to cause
increases in free radicals in neurons (Subbarao
et al., 1990; Mecocci et al., 1994; Nunomura et
al., 1999) and glia (Brown et al., 2000), di-
rectly producing hydrogen peroxide through
metal ion reduction (Huang et al., 1999). This
suggests that Aβ may play a direct role in
increasing oxidative stress in the AD brain.
We examined the ability of Aβ to activate the
alternative pathway in human cells in cul-
ture. We found that Aβ increases the levels of
cellular reactive oxygen species and DHEA
after 24 hours of treatment. Both of these
increases could be blocked by co-treatment
with Vitamin E, an anti-oxidant (Brown et al.,
2000). These data suggested that the alterna-
tive pathway for DHEA synthesis could be
important in pathological conditions involv-
ing increased oxidative stress. Furthermore, in
tissue samples isolated from the hippocam-
pus, hypothalamus and frontal cortex of se-
vere AD patients (containing high levels of
Aβ), the levels of DHEA were significantly in-
creased as compared to age-matched controls.
We believe this to be representative of the in-
creased Aβ-induced oxidative stress thought
to be the hallmark of the pathogenesis of
AD (Markesbery, 1997). Interestingly, CYP17
was not found in the human hippocampus
by immunohistochemistry or RT-PCR fol-
lowed by Southern blot analysis (Brown et al.,
2003). Treatment of hippocampus and hypo-
thalamus with FeSO4 caused an increase in
DHEA levels in control but not inAD patients
(Brown et al., 2003), suggesting that the levels
of the DHEA precursor in control are higher
than in AD specimens. These results indicate
that DHEA is formed in the AD brain by the
oxidative stress-mediated metabolism of an
unknown steroid precursor (probably due to
increased levels of Aβ).
To test the hypothesis that there is a CYP17-
indepednent pathway of DHEA formation
we attempted to generate mice with a tar-
geted deletion of CYP17 (Liu et al., 2005).
If CYP17 is indeed not involved in brain
DHEA formation, then we could focus our
efforts on the characterization of the biochem-
ical pathway responsible for DHEA forma-
tion in brain. Although in chimeric mice,
Leydig cell CYP17 mRNA and intratesticu-
lar and circulating testosterone levels were
dramatically reduced, the remaining testos-
terone was sufficient to support spermato-
genesis as evidenced by the generation of
phenotypical black C57BL/6 mice. However,
male chimeras consistently failed to gener-
ate heterozygous CYP17 mice and after five
matings, chimeric mice stopped mating in-
dicating a change in sexual behavior. These
results suggested that CYP17 deletion caused
a primary phenotype (infertility) probably not
due to the anticipated androgen imbalance
and a secondary phenotype (change in sexual
behavior) due to the androgen imbalance. Sur-
prisingly, CYP17 mRNA was found in mature
sperm, and serial analysis of gene expression
identified CYP17 mRNA in other testicular
germ cells. CYP17 mRNA levels were directly
related to percent chimerism. Moreover, more
than 50% of the sperm from high percentage
chimeric mice were morphologically abnor-
mal and half of them failed the swim test. Fur-
thermore, 60% of swimming abnormal sperm
was devoid of CYP17. These results suggest
that YP17, in addition to its role in steroido-
genesis and androgen formation, is present in
germ cells where it is essential for sperm func-
tion and deletion of one allele prevents genetic
transmission of mutant and wild-type alleles
causing infertility followed by change in sex-
ual behavior due to androgen imbalance (Liu
et al., 2005). The next step will be to examine
the levels of DHEA in the brain of wild-type
BIOSYNTHESIS AND REGULATION OF DEHYDROEPIANDROSTERONE (DHEA) IN BRAIN 143
and chimeric mice carrying the CYP17 gene
deletion.
In conclusion, the generated data provides
evidence that CYP17 is not involved in brain
DHEA formation. Considering our findings
that brain DHEA formation is regulated by
oxidative stress, and triggered by iron and Aβ
both in vitro and in vivo, and the recent con-
firmation of these findings by an independent
group (Maayan et al., 2005), it is evident that
the next steps in our studies would be to pro-
vide the final evidence for the role of CYP17 in
brain DHEA synthesis by examining the lev-
els of DHEA in the brain of CYP17 chimeric
mice and identify the mechanism(s) responsi-
ble for brain DHEA synthesis and regulation.
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